ProCE Banner Activity

Pneumococcal Vaccines for Adults: A Matter of Choice?

Clinical Thought

Recent updates regarding adult pneumococcal vaccines in the United States and Europe are aimed at improving protection against serious infections and adapting to evolving disease-causing serotypes. These changes reflect ongoing efforts to enhance vaccine effectiveness and public health outcomes in both regions.

Released: September 16, 2024

Expiration: September 15, 2025

Share

Faculty

Elisabeth Botelho-Nevers

Elisabeth Botelho-Nevers, MD, PhD, HDR

Full Professor in Infectious Diseases
Head of Infectious Disease Department
University Hospital Saint-Etienne
CIRI Lab, Team GIMAP, Inserm, U1111, CNRS, UMR530
Chair Prevention, Vaccination, Controle de l’infection - PRESAGE
University of Saint-Etienne
Saint-Etienne, France

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Merck & Co., Inc., Rahway, NJ, USA

Disclosure

Primary Author

Elisabeth Botelho-Nevers, MD, PhD, HDR

Full Professor in Infectious Diseases
Head of Infectious Disease Department
University Hospital Saint-Etienne
CIRI Lab, Team GIMAP, Inserm, U1111, CNRS, UMR530
Chair Prevention, Vaccination, Controle de l’infection - PRESAGE
University of Saint-Etienne
Saint-Etienne, France

Elisabeth Botelho-Nevers, MD, PhD, HDR: consultant/advisor/speaker: GlaxoSmithKline, Merck Sharp & Dohme, Moderna, Pfizer, Sanofi Pasteur; researcher: GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Moderna, Pfizer, Sanofi Pasteur.